Concepts (58)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 4 | 2023 | 2722 | 0.670 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2019 | 44 | 0.650 |
Why?
|
| Periosteum | 1 | 2019 | 39 | 0.650 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2023 | 6776 | 0.530 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 931 | 0.430 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2652 | 0.270 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 28 | 0.230 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 344 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 362 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 266 | 0.170 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 246 | 0.170 |
Why?
|
| Transplantation Conditioning | 4 | 2023 | 2301 | 0.170 |
Why?
|
| RNA, Viral | 1 | 2022 | 690 | 0.160 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 495 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 7068 | 0.160 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 370 | 0.140 |
Why?
|
| Acute Disease | 1 | 2022 | 2471 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2019 | 298 | 0.140 |
Why?
|
| Child | 7 | 2023 | 30200 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 1459 | 0.110 |
Why?
|
| Alemtuzumab | 2 | 2023 | 208 | 0.100 |
Why?
|
| Neuroblastoma | 1 | 2017 | 695 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 2850 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2023 | 16792 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2379 | 0.070 |
Why?
|
| Humans | 10 | 2023 | 270843 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2017 | 3481 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2023 | 39512 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 189 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 215 | 0.050 |
Why?
|
| Texas | 2 | 2021 | 6460 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2021 | 322 | 0.040 |
Why?
|
| Busulfan | 1 | 2023 | 778 | 0.040 |
Why?
|
| Melphalan | 1 | 2022 | 839 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 494 | 0.040 |
Why?
|
| Infant | 2 | 2023 | 13818 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 2944 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 1979 | 0.040 |
Why?
|
| Rituximab | 1 | 2022 | 1557 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 3144 | 0.030 |
Why?
|
| Cytarabine | 1 | 2022 | 1993 | 0.030 |
Why?
|
| Recurrence | 1 | 2023 | 4876 | 0.030 |
Why?
|
| Neoplasms | 1 | 2021 | 15710 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 32336 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1627 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 10257 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 13310 | 0.020 |
Why?
|
| Female | 1 | 2019 | 147292 | 0.020 |
Why?
|
| Aged | 2 | 2022 | 72902 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 9010 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 7170 | 0.010 |
Why?
|
| Survival Rate | 1 | 2017 | 12451 | 0.010 |
Why?
|
| Young Adult | 1 | 2022 | 22140 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 16270 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 34238 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 80709 | 0.010 |
Why?
|
| Middle Aged | 1 | 2022 | 89535 | 0.010 |
Why?
|
| Male | 1 | 2021 | 127630 | 0.010 |
Why?
|